PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to assess whether prophylactic treatment with metoprolol or losartan is able to reduce the incidence of atrial fibrillation (AF) in patients undergoing thoracic surgery for lung cancer, showing elevated plasma levels in NT probrain natriuretic peptide (NT-proBNP), measured in the perioperative period.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: European Institute of Oncology
• Treatments: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Losartan; Metoprolol

Criteria

Inclusion Criteria:

• Patients of both sexes with age ≥ 18 years

• Thoracic surgery for lung cancer

• Evidence of elevated perioperative NT-proBNP

• Written informed consent

Exclusion Criteria:

• Hypersensitivity and / or intolerance to metoprolol or losartan

• History of heart failure

• Left ventricular ejection fraction <50% measured by echocardiographic techniques (Simpson rule)

• Permanent atrial fibrillation

• Antiarrhythmic therapy

• Current therapy with beta-blockers, angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors

• Systolic blood pressure <95 mmHg

• Pregnant and lactating women

Additional exclusion criteria for therapy with beta-blocker:

• History of sick sinus syndrome, evidence of AV-block grade II or greater

• Heart rate <65 b / m

• History of bronchial asthma, severe bronchopneumopathy, evidence of bronchospasm